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actions of vitamin D
Evidências das ações não esqueléticas da vitamina D
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Summary
Vitamin D is a major regulator of mineral homeostasis through its action in the kidney, intes-
tine, bone and parathyroid glands. On these tissues, its active form, calcitriol, acts by binding 
to a specific nuclear receptor that belongs to the steroid/thyroid hormone receptor family. This 
receptor, however, has also been identified in several additional human tissues. So, apart from 
its traditional actions related to calcium, vitamin D and its synthetic analogs are being increasin-
gly recognized for their anti-proliferative, pro-differentiative and immunomodulatory activities. 
Low levels of vitamin D have been linked to many chronic diseases. Decreased muscle function 
and increased fall risk in elderly people; prostate, breast and colorectal cancers; diabetes melli-
tus; and other health problems have been associated to low circulating levels of 25-hydroxyvita-
min D. This paper presents an overview of the available scientific evidence for the non-calcemic 
actions of vitamin D in humans. Arq Bras Endocrinol Metab. 2010;54(2):110-7
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Sumário
A vitamina D é um importante regulador da homeostase mineral por meio de sua ação nos 
rins, no intestino, nos ossos e nas glândulas paratireoides. Nesses tecidos, sua forma ativa, o 
calcitriol, atua ligando-se a um receptor nuclear específico, pertencente à família de receptores 
dos hormônios esteroides e tireoidianos. Contudo, esse receptor também foi identificado em 
outros tecidos humanos. Assim, além de suas ações tradicionais, relacionadas ao metabolismo 
do cálcio, a vitamina D e análogos sintéticos estão, cada vez mais, sendo reconhecidos por seus 
efeitos antiproliferativos, pró-diferenciação e imunomodulatórios. Baixas concentrações séricas 
de vitamina D têm sido associadas a várias doenças crônicas. Redução da função muscular e 
aumento do risco de quedas em idosos; câncer de próstata, mama e colorretal; diabetes melito; 
e outros problemas de saúde têm sido associados a concentrações circulantes baixas de 25-hi-
droxivitamina D. Este trabalho apresenta uma visão geral sobre as evidências científicas dispo-
níveis das ações não calcêmicas da vitamina D em humanos. Arq Bras Endocrinol Metab. 2010;54(2):110-7
Descritores
Vitamina D; metabolismo; deficiência; câncer; força muscular; cálcio
iNTroDuCTioN
Vitamin D3 is truly a prohormone rather than a vita-min. It is produced in the skin through ultraviolet 
irradiation of 7-dehydrocholesterol (Figure 1). Some 
nutrients like fatty fish, eggs and dairy products also 
contain vitamin D3, but they are not consumed as fre-
quently as necessary for an essential dietary factor. Our 
main source of vitamin D3 is endogenous production 
(1). The adequate requirement of vitamin D may be 
achieved if the exposition of the skin with solar ultravio-
let radiation occurs in a regular and safe manner. This 
correlation between sun exposure and plasma concen-
trations of 25-hydroxyvitamin D (25OHD) becomes 
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apparent when evaluated over the months of the year. 
There is a clear seasonal variation in these levels in the 
elderly and even in young people (2,3). In an elderly 
population living in Sao Paulo, Brazil, 25OHD levels 
after summer are twice as high as those observed after 
winter, at 67.2 nmol/L and 29.1 nmol/L, respectively 
(2). In young people living in this same city we also 
found a seasonal variation but of lower magnitude; 
their summer 25OHD levels were approximately 30% 
higher than winter concentrations (3). 
Thanks to migratory movements in the world 
population and the behavioral changes witnessed in 
the last century, body sun expositions have become 
rare, and vitamin D deficiency has reached epidemic 
rates worldwide (4). Even in sunny countries such as 
Brazil data are impressive: 71.2% of the institutional-
ized and 55.8% of the free-living elderly from the city 
of Sao Paulo (23°S) had very low levels of 25OHD 
(< 50 nmol/L and < 20 ng/mL), with almost the same 
proportion of secondary hyperparathyroidism, 61.7% 
and 54.0%, respectively (Figure 2) (5). For practical 
reasons we should keep in mind that an exposure time 
of 10 minutes three times per week of unprotected head 
and arms would be adequate to prevent vitamin D de-
ficiency (4,6,7).
A meta-analysis of randomized, controlled trials 
published in 2007 reviewed the association between 
vitamin D supplementation and total mortality. The 
mean daily dose of vitamin D supplements ranged from 
400 IU to 833 IU. The authors concluded that the in-
take of ordinary doses of vitamin D supplements seems 
to be associated with decreases in total mortality. The 
relationship between baseline vitamin D status, dose 
of vitamin D supplements and total mortality rates re-
mains to be investigated (8).
ViTamiN D mETaBoLiSm
Vitamin D is denominated a secosteroid because 
one of the rings of its cyclopentanoperhydrophenan-
threne structure has a broken carbon-carbon bond 
(Figure 1). Vitamin D3 undergoes two hydroxylation 
reactions, a hepatic 25-hydroxylation and a renal 
1-α-hydroxylation, to produce the active hormone 
1α,25 dihydroxyvitamin D3 [1,25(OH)2D3]. The ste-
roid hormone 1,25(OH)2D3 interacts with a single vi-
tamin D receptor in the cell nucleus to exert its biologi-
cal functions. It is well known that the active metabolite 
1,25(OH)2D3 plays an important role in bone mineral 
metabolism and health, however, 1,25(OH)2D3 has a 
wide range of non-calcemic actions that are also useful 
for promoting optimal health (7,9,10).
Vitamin D receptor (VDR) is a phosphoprotein 
member of the nuclear receptor superfamily that 
functions as a ligand-dependent transcription factor. 
VDR binds as a heterodimer with retinoid X recep-
tor (RXR) to hexameric repeats, characterized as vita-
min D responsive elements present in the regulatory 
region of many target genes such as osteocalcin, os-
teopontin, calbindin-D28K, calbindin-D9K, TGF-β2 
and vitamin D 24-hydroxylase. Many factors such 
as glucocorticoids, estrogens, retinoids, cell prolif-
eration rate and transformation can modulate VDR 
levels (11). The molecular cloning of VDR and the 
identification of its widespread expression in human 
tissues led researchers to suspect that the vitamin D 
endocrine system has additional physiological func-
tions beyond calcium homeostasis. Vitamin D and 
VDR have been shown to play important roles in the 
immune, cardiovascular and reproductive systems and 
in hair growth. The few cells or tissues that have low 
or absent VDR expression include red blood cells, 
mature striated muscle cells and some differentiated 
brain cells, such as Purkinje cells of the cerebellum 
(10). An important step in studying the functions 
of 1,25(OH)2D3 was the generation of VDR- and 
1α-hydroxylase-null mice (12). Table 1 summarizes 
features of nontraditional 1,25(OH)2D3 target tissues 
in VDR-null mice. 
Figure 1. Photobiosynthesis of vitamin D
3
 in skin. 
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Figure 2. Concentrations of 25 hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) in three different populations living in the city of Sao Paulo, 
Brazil (23°S): institutionalized and free-living elderly people, compared to young normal controls (5). The marked boxes define the normal range values for 
both hormones. 
Table 1. Non-classical 1α,25-dihydroxyvitamin D3 target tissues in VDR-
null mice models 
Tissue Feature
Skin Alopecia
Abnormal hair cycling
Anti-proliferative and pro-differentiative effect on 
keratinocytes
Muscle Smaller muscle fibers
Persistent expression of early markers of myogenic 
differentiation
Cardiovascular 
system
High renin hypertension 
Cardiac hypertrophy 
Immune system Impaired macrophage function
Abnormal Th1 macrophage-induced formation 
Increased number of immature dendritic cells
Predisposition to autoimmune diseases such as type 1 diabetes
Decreased monocytic differentiation and antibacterial activity 
of monocytes
Pancreas β 
cells
Normal glucose tolerance or mild glucose intolerance
Is a target tissue with discrepancy between effects of the 
vitamin D ligand and the VDR itself
Brain Abnormal behavior, especially muscle and motor behavior
Cell 
proliferation/
Cancer
Hyperproliferation of colonic cells 
Dysregulated growth of alveolar and ductal mammary gland cells
Enhanced susceptibility to chemocarcinogen-induced 
leukemia
Reproductive 
system
Uterine hypoplasia 
Impaired ovarian folliculogenesis
Male infertility
Based on references 9, 21, 40, 52 and 53.
ViTamiN D DEFiCiENCy aND NoN-SKELETaL 
DiSEaSES
Low levels of vitamin D have been linked to many chron-
ic conditions and diseases. Epidemiological findings, 
genetic studies and clinical trials have been published 
and have shown strong evidence of this linkage (13,14). 
A great number of in vitro studies give support to these 
epidemiological and clinical findings. 1,25(OH)2D3 has 
potent anti-proliferative and pro-differentiative effects 
in a wide variety of cell types, and its effects have been 
tested in different types of cancer cells such as prostate, 
breast, ovarian, colorectal, squamous, and leukemia 
cells. The variety of target genes identified through these 
studies reflects the pleiotropic action of 1,25(OH)2D3. 
Common cellular processes targeted by 1,25(OH)2D3 in 
different cancer cell lines include cell-cycle progression, 
apoptosis, cellular adhesion, oxidative stress, immune 
function and steroid metabolism (15). This review men-
tions some of the most important diseases.
Breast cancer
Epidemiologic studies have shown an inverse relation-
ship between sun exposure and a higher incidence of 
breast cancer (12). A recent meta-analysis of vitamin D 
and the prevention of breast cancer found a 45% de-
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crease in breast cancer risk for those in the highest 
quartile of circulating 25OHD (60 nmol/L) compared 
to those with the lowest level. No relationship was 
found between the level of circulating 1,25(OH)2D3 
and breast cancer (16). 
VDR is expressed in mammary tissue and breast can-
cer cells which are potential targets for hormone action. 
Besides having anti-proliferative properties, vitamin D 
might also reduce the invasiveness of cancer cells and 
act as an anti-angiogenesis agent (12). Another piece of 
evidence that links vitamin D and breast cancer is the 
fact that the chromosomal region 20q13.2, which con-
tains 24-hydroxylase is amplified in breast cancer (12). 
Because 24-hydroxylase is involved in 1,25(OH)2D3 
degradation, its amplification may lead to decreased 
serum levels of vitamin D providing an environment 
conducive for cell growth in the absence of vitamin 
D-mediated growth control. The exact mechanism 
underlying the growth inhibitory actions of vitamin D 
in breast cancer is not clear, but data support that the 
effect of vitamin D may involve growth arrest at the 
G0/G1 stage, cell apoptosis or disruption of estrogen 
and other growth factor-mediated cell survival signals 
and angiogenesis (12). All of these anti-tumoral fea-
tures suggest that the properties of vitamin D and VDR 
could be explored for therapeutic purposes in breast 
cancer, and different 1,25(OH)2D3 analogs with potent 
anti-proliferative but lesser hyper-calcemic effects are 
being developed and tested for clinical use (9).
Colon cancer
Epidemiological studies have suggested the involve-
ment of vitamin D in the pathogenesis of colorectal tu-
mors. An inverse association has been reported between 
vitamin D levels and colon cancer incidence (12). In-
creased VDR protein was found in colonic tumors more 
than in their normal counterparts (12). Apart from 
possessing VDR, colonic cells also posses the ability to 
synthesize 1,25(OH)2D3 from 25-hydroxyvitamin D3 
by the local action of 1(-hydroxylase activity. Despite 
all of these facts, a recent randomized, double-blind, 
placebo-controlled trial involving 36,282 women from 
the Women’s Health Initiative found that daily supple-
mentation of calcium (1,000 mg) with vitamin D (400 
IU) for seven years had no effect on the incidence of 
colorectal cancer among postmenopausal women. On 
the other hand, an intake of 2000 UI/day of vitamin D 
may reduce by 27% the incidence of colorectal cancer in 
North America (17,18).
Prostate cancer
Laboratory in vitro studies have demonstrated that 
1,25(OH)2D3 and its synthetic analogs inhibit the pro-
liferation of prostate cancer cell lines (12). Epidemio-
logical studies have also shown that increased exposure 
to UV light may be protective against prostate cancer, 
but this finding has been conflicting and requires fur-
ther investigation to support the association. Polymor-
phisms of the VDR gene that affect the receptor bind-
ing of 1,25(OH)2D3 may modify vitamin D’s biological 
activity and confer different susceptibility to prostate 
cancer. In a recent meta-analysis performed by Yin and 
cols. (19), 36 publications on the association of Taql, 
Apal, Bsml, Fokl and CDx2 single nucleotide polymor-
phisms in susceptibility to prostate cancer were identi-
fied. The authors suggested that Taq 1 t and Bsm 1 
B alleles were associated with reduced prostate cancer 
risk among all study populations, whereas the Fok 1 f 
allele was associated with increased cancer risk among 
Caucasian populations (19). According to recent evi-
dence, 25OHD may play a role in the regulation of 
cell proliferation in the prostate. It is mainly acting di-
rectly through the VDR, but it may also partially act 
through its 1alpha-hydroxylation in the prostate. A lack 
of vitamin D action may also be due to an altered me-
tabolism or vitamin D resistance. Vitamin D resistance 
might be brought up by several mechanisms, and the 
local metabolism of hormonal vitamin D seems to play 
an important role in the development and progression 
of prostate cancer (20).
Leukemia
1,25(OH)2D3 plays a role in the regulation of the 
immune system. Cells of the monocyte/macrophage 
lineage possess receptors for 1,25(OH)2D3 regard-
less of their activation stage. Further, 1,25(OH)2D3 
promotes the differentiation of monocyte precur-
sors towards monocyte/macrophages and enhances 
monocyte function in antigen presentation. In addi-
tion, 1,25(OH)2D3 modulates cytokine production by 
lymphocytes (21).
Although one of the first described non-classical 
vitamin D actions was its ability to promote differ-
entiation and block proliferation of murine myeloid 
leukemia, clinical trials up to this point have failed to 
obtain good results in clinical management when they 
use 1,25(OH)2D3 and analogs to treat myelodysplastic 
syndromes and myeloid leukemia (22). 
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
114 Arq Bras Endocrinol Metab. 2010;54/2
Non-skeletal actions of vitamin D
multiple sclerosis
Epidemiological studies have related an increase of 
multiple sclerosis with increasing geographical latitude. 
Clinical studies have shown that vitamin D levels are 
lower among patients with multiple sclerosis. There is 
also evidence that UV light and calcitriol reduce the 
symptoms of multiple sclerosis (23). 
Type 1 diabetes
Vitamin D deficiency is largely described in diabetes 
mellitus type 1 (T1DM) patients from different origins 
(24,25). Vitamin D deficiency has been associated with 
an increased risk of T1DM. Glycemic control and insu-
lin resistance are improved when vitamin D deficiency 
is corrected and calcium supplementation is adequate. 
Studies have also shown an increase in the incidence of 
T1DM when vitamin D deficiency was present in the 
first month of life in children (12,23). VDR gene poly-
morphisms may be associated with the risk of develop-
ing T1DM, but reports have been conflicting (26,27). 
Because 1,25(OH)2D3 has very well established in vitro 
effects on insulin secretion and on immunological re-
sponse, there are some suggestions that vitamin D defi-
ciency may play a role in the development of type 1 dia-
betes, although this hypothesis is still to be confirmed. 
Type 2 diabetes
Several reports have demonstrated a role of vitamin D in 
the functional regulation of pancreatic beta cells (28). 
The identification of receptors for 1,25(OH)2D3 (29) 
and the expression of 1α-hydroxylase enzyme in pan-
creatic beta cells (30) support a role of vitamin D in 
pancreatic beta cells. Vitamin D deficiency inhibits pan-
creatic secretion of insulin (31) and is associated with 
glucose intolerance (32). Vitamin D is essential for 
insulin release (33), while vitamin D supplementation 
restores insulin secretion (34). In peripheral insulin tar-
get tissues vitamin D may enhance insulin sensitivity 
by stimulating the expression of insulin receptors (35). 
A large cross-sectional survey showed a signifi-
cant inverse association between serum 25OHD and 
diabetes prevalence (36). Recent prospective analysis 
from an English cohort reported inverse associations 
between baseline serum 25OHD and future glycemic 
status and insulin resistance (37), and a Finnish cohort 
study showed an inverse association between baseline 
serum 25OHD and the 17-year risk of type 2 diabe-
tes (38). The Nurse’s Health Study (39) demonstrated 
that women with an average vitamin D daily intake 
> 800 UI had a 33% lower risk of the incidence of type 
2 diabetes compared to an intake < 200 UI.
In spite of these observational data supporting the 
role of vitamin D in the development of type 2 diabetes, 
it is unlikely that vitamin D deficiency would be a major 
cause of this disease. Further cohort studies are required 
to test the hypothesis that vitamin D deficiency is a cause 
of diabetes, and we clearly need more evidence that vi-
tamin D supplementation reduces the risk of diabetes.
muscle function
Several studies have shown that vitamin D metabolites 
affect muscle cell metabolism through various pathways: 
by mediating gene transcription, through rapid pathways 
not involving DNA synthesis and by the allelic variant of 
the VDR (40). Both in animal models and in humans, 
a VDR has been found in skeletal muscle cells that spe-
cifically binds 1,25(OH)2D3. Vitamin D supplementa-
tion induces rapid changes in calcium metabolism of the 
muscle cell that cannot be explained by a slow genetic 
pathway. Evidence indicates that 1,25(OH)2D3, possibly 
through a vitamin D membrane receptor, acts direct-
ly on the muscle cell membrane. Upon 1,25(OH)2D3 
binding, several interacting second-messenger pathways 
were activated in the muscle cell, resulting in enhanced 
calcium uptake. Muscle strength also appears to be in-
fluenced by the genotype of the VDR in the muscle cell. 
Various cases have been described in which prolonged 
vitamin D deficiency was associated with severe muscle 
weakness, often leading to a marked disability that im-
proved with vitamin D supplementation. However, few 
studies have been conducted in which muscle strength 
was objectively quantified in relation to vitamin D status 
(10,41-43). In a prospective, double-blind, placebo-con-
trolled, randomized trial with Brazilian institutionalized 
elderly people we showed that a 6-month vitamin D sup-
plementation significantly improved lower limb muscle 
strength in the absence of any regular physical exercise 
practice (Figure 3) (44). 
Vitamin D deficiency has also been related to an 
increase in the incidence of falls. A recent systematic 
review including eight prospective, double-blind, ran-
domized, controlled studies suggests that vitamin D in 
doses of 700 to 1000 UI/day may reduce the risk of an 
elderly person falling by 19%. Doses of supplemental vi-
tamin D less than 700 IU or serum 25-hydroxyvitamin 
D concentrations than 60 nmol/L may not reduce the 
risk of falling among older individuals (45). 
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Figure 3. Evaluation of the Strength of Hip Flexors (SFH) after six-month vitamin D replacement in institutionalized elderly. (A) Shows the significant 
increment in SFH observed in the group that received vitamin D
3
 treatment (average of 3600 UI/day), which was not seen in the placebo group. (B) 
Demonstrates that the SFH increment was seen only in those who had lower levels of 25OHD levels at baseline (< 50 nmol/L) (43). 
Cardiovascular disease
Recent evidence suggests that vitamin D may play a role 
in mortality risk. The major circulating form of vitamin 
D, 25OHD, has been associated with all causes of mor-
tality in individuals with end-stage renal disease and 
coronary artery disease and even in the general popu-
lation (46). Further evidence suggests that vitamin D 
supplementation may lower mortality. Several mecha-
nisms can be considered in the relationship between vi-
tamin D and cardiovascular disease (CVD). The first is 
the effect on the renin-angiotensin system (RAS) (47). 
As vitamin D inhibits renin activity, vitamin D deficien-
cy activates RAS. Vitamin D also has protective effects 
on CVD by suppressing cardiac hypertrophy. As inflam-
mation is involved in atherosclerosis, which is CVD’s 
basic clinical condition, vitamin D possibly suppresses 
CVD events through its anti-inflammatory function. 
This indicates that vitamin D is influential in the inhibi-
tion of CVD events from different pathways (48).
Psychiatric and neurologic disorders
Vitamin D deficiency is common in older adults and 
has been implicated with psychiatric and neurological 
disorders such as depression, multiple sclerosis, fibro-
myalgia, schizophrenia and Parkinson’s disease. De-
pression has incidentally been related to altered levels 
of 25OHD, but this relation has never been studied 
systematically. Murphy and Wagner (49) evaluated, in 
an integrative review, studies that investigated the as-
sociation between vitamin D and mood disorders in 
women. The authors found a significant association be-
tween mood disorders and low 25OHD levels in four 
of six studies, indicating that some biochemical mecha-
nism may exist between these two variables. In a cross-
sectional study to investigate the relationship among 
vitamin D status and cognitive performance, mood 
and physical performance in older adults, the authors 
showed that vitamin D deficiency was associated with 
low mood and impairment in two of four evaluations 
of cognitive performance (50). A large prospective study 
found that high circulating levels of vitamin D were associ-
ated with a lower risk of multiple sclerosis (51). Besides 
that, a large population-based cohort study demon-
strated an association between depression status and se-
verity with decreased circulating levels of 25OHD and 
increased serum PTH levels in older individuals (52). 
These associations warrant further studies to confirm 
the influence of vitamin status on psychiatric and neu-
rological disorders. 
microbial infections
The innate immunity plays a critical role in human de-
fense. The innate immune response includes recogni-
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tion of microbial invasion and production of antimicro-
bial peptides such as defensins and cathelicidins (10). 
The discovery of VDR expression in activated inflam-
matory cells signalized the importance of vitamin D 
and the active form 1,25(OH)2D3 in the immune func-
tion (53). Exposing monocytes and macrophages to 
1,25(OH)2D3 improves their chemotactic and phago-
cytic capacity, features that are indispensable for their 
tumor cell cytotoxicity and microbacterial activity (10). 
The current vitamin D-dependent antimicrobial immu-
nity model proposes that when a pathogen is detected 
by its respective Toll-like receptor (pattern-recognition 
receptor), VDR and 1α-hydroxylase gene expression 
are induced (10,53). This leads to 1α-hydroxylation of 
25OHD, which is taken up from the blood, and subse-
quent binding of 1,25(OH)2D3 to the VDR. The cath-
elecidin gene is activated and its respective protein is 
synthesized for use against the pathogen that has been 
engulfed in the phagosome of the macrophage (53).
Elevated 1,25(OH)2D3 and hypercalcemia have 
been associated with active pulmonary tuberculosis, 
and epidemiological studies have demonstrated that 
lower serum concentration of 25OHD correlates with 
increased susceptibility to tuberculosis (54). The ben-
eficial effects of vitamin D supplementation on treat-
ment of tuberculosis have been studied in randomized 
clinical trials, but conflicting results have been reported 
(53). Further clinical trials are needed to elucidate the 
potential therapeutic applications of vitamin D and its 
synthetic analogs against tuberculosis and other infec-
tious diseases (53).
CoNCLuSioN
In the last twenty years, vitamin D and its non-classical 
actions have taken an important place in the clinical 
scenario. After this discovery, many epidemiological 
and interventional studies have proved the benefits of 
vitamin D sufficiency status in promoting good health. 
The search for vitamin D synthetic analogs without cal-
cemic activity will allow the promising clinical use of 
these hormone analogs in the prevention and treatment 
of chronic diseases, like cancer, diabetes, muscle weak-
ness and autoimmune diseases.
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